PriceSensitive

Thorney Investment Group earns 5.2pc stake in Zelira Therapeutics (ASX:ZLD)

Health Care
ASX:ZLD      MCAP $8.17M
23 September 2020 10:30 (AEST)
Zelira Therapeutics (ASX:ZLD)- Chairman,Osagie Imasogie

Source: Satellinstitute

Medical cannabis company Zelira Therapeutics (ZLD) has a new substantial holder after Thorney Investment Group made a $2 million strategic investment.

Under a private placement, the healthcare company issued over 37 million new shares — priced at 5.4 cents each — to Thorney, which increased its holding to a 5.2 per cent stake.

Zeilra says the funds raised under the placement will be used to fast-track the commercialisation of its product pipeline

In addition, subject to shareholder approval, Zelira will issue Thorney a one-for-one free attaching unquoted option, exercisable at seven cents each, which will expire two years from the date of issue.

“While the global medicinal cannabinoid sector has many entrants, we believe Zelira is well placed with its life science approach to take advantage of multiple opportunities in multiple jurisdictions,” Thorney Chairman Alex Waislitz said.

“The strategic focus on intellectual property protection, together with its capital light business model we believe positions the company strongly as it commences revenue generation,” he added.

Zelira’s Chairman, Osagie Imasogie, is pleased to have Thorney has a substantial investor in the company.

“With a strong balance sheet and a supportive strategic partner, Zelira is well positioned to accelerate its path to commercialisation in global markets,” he said.

Last week, the company launched its proprietary cannabinoid medicine, Zenivol, in Australia.

On the back of the news, Zelira shares have spiked 1.59 per cent in early trade, worth 6.4 cents each at 10:48 am AEST.

Related News